Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert A Fletcher

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Journal of Cardiac Failure|July 4, 2025
Albuminuria, Kidney Function and Heart Failure Risk in Type 2 Diabetes: Participant-level Pooled Analysis from the CANVAS Program and CREDENCE TrialJeffrey T Ha, Robert A Fletcher, Clare Arnott, et al.
The Lancet. Planetary Health|December 14, 2024
The potential for reducing greenhouse gas emissions through disease prevention: a secondary analysis of data from the CREDENCE trialBenjamin Talbot, Robert A Fletcher, Bruce Neal, et al.
Diabetes, Obesity & Metabolism|October 26, 2023
Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trialAbhinav Sharma, Pedro Marques, Brendon L Neuen, et al.
Diabetes, Obesity & Metabolism|January 19, 2023
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trialAkihiko Koshino, Megumi Oshima, Clare Arnott, et al.
Diabetes, Obesity & Metabolism|May 15, 2023
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trialsVikas S Sridhar, Brendon L Neuen, Robert A Fletcher, et al.
European Journal of Heart Failure|January 23, 2025
Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trialsSafia Chatur, Muthiah Vaduganathan, Robert A Fletcher, et al.
Kidney International Reports|July 9, 2025
Corticosteroid Effects in IgA Nephropathy by Baseline Proteinuria and Estimated GFRDana Kim, Brendon L Neuen, Jicheng Lv, et al.
Circulation|August 30, 2024
Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-AnalysisBrendon L Neuen, Robert A Fletcher, Lauren Heath, et al.
Diabetes, Obesity & Metabolism|May 29, 2024
Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trialNavdeep Tangri, Thomas W Ferguson, Ryan J Bamforth, et al.
Kidney International|April 29, 2023
Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trialsHiddo J L Heerspink, Niels Jongs, Brendon L Neuen, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Journal of Cardiac Failure|July 4, 2025
Albuminuria, Kidney Function and Heart Failure Risk in Type 2 Diabetes: Participant-level Pooled Analysis from the CANVAS Program and CREDENCE TrialJeffrey T Ha, Robert A Fletcher, Clare Arnott, et al.
The Lancet. Planetary Health|December 14, 2024
The potential for reducing greenhouse gas emissions through disease prevention: a secondary analysis of data from the CREDENCE trialBenjamin Talbot, Robert A Fletcher, Bruce Neal, et al.
Diabetes, Obesity & Metabolism|October 26, 2023
Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trialAbhinav Sharma, Pedro Marques, Brendon L Neuen, et al.
Diabetes, Obesity & Metabolism|January 19, 2023
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trialAkihiko Koshino, Megumi Oshima, Clare Arnott, et al.
Diabetes, Obesity & Metabolism|May 15, 2023
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trialsVikas S Sridhar, Brendon L Neuen, Robert A Fletcher, et al.
European Journal of Heart Failure|January 23, 2025
Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trialsSafia Chatur, Muthiah Vaduganathan, Robert A Fletcher, et al.
Kidney International Reports|July 9, 2025
Corticosteroid Effects in IgA Nephropathy by Baseline Proteinuria and Estimated GFRDana Kim, Brendon L Neuen, Jicheng Lv, et al.
Circulation|August 30, 2024
Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-AnalysisBrendon L Neuen, Robert A Fletcher, Lauren Heath, et al.
Diabetes, Obesity & Metabolism|May 29, 2024
Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trialNavdeep Tangri, Thomas W Ferguson, Ryan J Bamforth, et al.
Kidney International|April 29, 2023
Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trialsHiddo J L Heerspink, Niels Jongs, Brendon L Neuen, et al.
Pageof 4